India’s small and medium-sized pharma manufacturers are set to face tighter regulatory scrutiny, with the Central Drugs Standard Control Organisation (CDSCO) directing state authorities to conduct inspections under the revised Schedule M manufacturing norms. The move marks the end of the grace period granted to MSME drugmakers for aligning with updated quality and safety standards.
According to Business Standard, the Drug Controller General of India (DCGI), Dr. Rajeev Raghuvanshi, has instructed states and union territories to begin enforcement planning immediately, signalling a shift from extension to execution. The directive comes as the one-year transition window for units with an annual turnover below ₹250 crore draws to a close.
Deadline Extended Until December 2025, Enforcement from January 2026
MSME pharma companies were given until December 31, 2025, to fully comply with the revised Schedule M, which governs Good Manufacturing Practices (GMP) for pharmaceutical production. Beginning January 1, 2026, all manufacturers must demonstrate adherence to the new standards or face potential regulatory action.
In a recent communication to state regulators, Raghuvanshi instructed:
“You are requested to initiate planning for inspections of manufacturing units who have applied for extension of revised Schedule M and whose effective date of implementation is January 1, 2026, to verify their compliance.”
The DCGI also directed states to submit monthly progress reports detailing inspection results, observations, and enforcement measures taken against non-compliant units.
Also read: Veloce Fintech Launches ₹300 Crore Fund to Support MSMEs and Startups
Rising Pressure on MSME Drugmakers to Upgrade Facilities
The revised Schedule M guidelines aim to bring India’s pharmaceutical manufacturing ecosystem closer to global quality benchmarks, covering facility design, documentation, sanitation, and process control. However, smaller drugmakers have raised concerns over high compliance costs, including investments in infrastructure upgrades, validation systems, and workforce training.
Industry associations have requested phased implementation support or subsidies for MSMEs struggling to absorb the financial impact. Analysts note that while tighter oversight is critical to maintaining India’s reputation as a global generic drug supplier, the transition may temporarily strain smaller firms that form the backbone of India’s pharma ecosystem.
The renewed inspection drive reflects a broader regulatory push to strengthen drug quality governance following recent global alerts about substandard exports from India.